AstraZeneca Imfinzi combination fails advanced lung cancer study [Reuters]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Reuters
AstraZeneca Imfinzi combination fails advanced lung cancer study - Reuters 3 Min Read (Reuters) - A combination of AstraZeneca’s lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations, the drugmaker said on Wednesday. The late-stage clinical trial was testing Imfinzi, chemically known as durvalumab, along with another treatment tremelimumab and compared the combination to platinum-based chemotherapy to treat patients whose cancer had spread beyond the lungs. London-listed AstraZeneca said that though the trial involved a wide range of patients, the primary group being tested had high levels of mutations in their DNA. The trial looked at stage IV patients - those with the most advanced form of cancer. “This (the result) is clearly disappointing, albeit we do not think hopes were especially high for the durvalumab plus tremelimumab combination given the relatively po
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Scholz Gets Another Pharma Boost With New Merck KGaA Site [BNN Bloomberg (Canada)]BNN Bloomberg
- WebMD Ignite Unveils HealthHub Interactive to Support Health Plans' Clinical Programs [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers posts Q1 beat despite growth headwinds [Seeking Alpha]Seeking Alpha
- Merck raises guidance as Keytruda sales jump 20% in Q1 [Seeking Alpha]Seeking Alpha
- Merck Raises Forecast as Sales of Its Cancer Immune Therapy Soar [BNN Bloomberg (Canada)]BNN Bloomberg
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 4/25/24 - Form 8-K
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- MRK's page on the SEC website